“The area under the plasma concentration-time curve (AUC) and the peak concentration (Cmax) of diltiazem were significantly (P < 0.05, 4 mg x kg(-1) and P < 0.01, 12 mg x kg(-1)) increased in the presence of EGCG.”
“The presence of EGCG significantly enhanced the oral bioavailability of diltiazem due to inhibiting cytochrome P450 (CYP) 3A4-mediated metabolism and P-glycoprotein (P-gp) mediated efflux of diltiazem in the intestine.”